Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 29.12M
March 31, 2026 29.06M
December 31, 2025 29.02M
September 30, 2025 21.39M
June 30, 2025 21.38M
March 31, 2025 21.38M
December 31, 2024 21.33M
September 30, 2024 21.19M
June 30, 2024 21.18M
March 31, 2024 21.18M
December 31, 2023 21.16M
September 30, 2023 21.06M
June 30, 2023 21.06M
March 31, 2023 21.05M
December 31, 2022 20.88M
September 30, 2022 20.79M
June 30, 2022 20.72M
March 31, 2022 20.62M
December 31, 2021 20.51M
September 30, 2021 20.24M
June 30, 2021 20.21M
March 31, 2021 20.18M
December 31, 2020 20.14M
September 30, 2020 20.08M
June 30, 2020 20.07M
Date Value
March 31, 2020 19.99M
December 31, 2019 19.81M
September 30, 2019 19.70M
June 30, 2019 19.68M
March 31, 2019 19.67M
December 31, 2018 19.44M
September 30, 2018 19.40M
June 30, 2018 19.36M
March 31, 2018 19.26M
December 31, 2017 19.15M
September 30, 2017 19.12M
June 30, 2017 19.09M
March 31, 2017 19.05M
December 31, 2016 19.04M
September 30, 2016 19.04M
June 30, 2016 19.04M
March 31, 2016 18.96M
December 31, 2015 18.80M
September 30, 2015 18.72M
June 30, 2015 18.71M
March 31, 2015 18.69M
December 31, 2014 18.61M
September 30, 2014 18.59M
June 30, 2014 18.58M
March 31, 2014 18.48M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Perspective Therapeutics, Inc. 114.09M
Coherus Oncology, Inc. 154.47M
BridgeBio Pharma, Inc. 195.28M
RenovoRx, Inc. 45.12M
ACADIA Pharmaceuticals, Inc. 172.13M